BTAI Insider Trading Activity and SEC Form 4 Filings
BTAI insider trading summary
Over the past 12 months, insiders at BioXcel Therapeutics, Inc. (BTAI) reported 4 sales worth $43K by 4 insiders and no open-market purchases on SEC Form 4. Net insider selling was $43K.
Latest BTAI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 20, 2026 | Vimal Mehta | CEO and President | Sell | $21K (19,419 @ $1.09) |
| May 20, 2026 | Richard I Steinhart | Chief Financial Officer | Sell | $7K (6,845 @ $1.08) |
| May 20, 2026 | Frank Yocca | Chief Scientific Officer | Sell | $7K (6,845 @ $1.08) |
| May 20, 2026 | Javier Rodriguez | See Remarks | Sell | $7K (6,560 @ $1.08) |
| Dec 16, 2024 | Frank Yocca | Chief Scientific Officer | Sell | $73 (205 @ $0.36) |
| Dec 16, 2024 | Vincent O'Neill | See Remarks | Sell | $58 (165 @ $0.35) |
| Dec 16, 2024 | Vimal Mehta | CEO and President | Sell | $773 (2,134 @ $0.36) |
| Dec 16, 2024 | Frank Yocca | Chief Scientific Officer | Sell | $79 (225 @ $0.35) |
| Dec 16, 2024 | Richard I Steinhart | Chief Financial Officer | Sell | $74 (205 @ $0.36) |
| Dec 16, 2024 | Richard I Steinhart | Chief Financial Officer | Sell | $133 (372 @ $0.36) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.